Predictive value of 18F-fluorodeoxyglucose PET/CT for transarterial chemolipiodolization of hepatocellular carcinoma

World Journal of Gastroenterology

Volumn 18, Issue 25, 2012, Pages 3215-3222

  Song, Myeong Jun ^a   Bae, Si Hyun ^a   Yoo, Ie Ryung ^a   Park, Chung Hwa ^a   Jang, Jeong Won ^a   Chun, Ho Jong ^a   Choi, Byung Gil ^a   Lee, Hae Giu ^a   Choi, Jong Young ^a   Yoon, Seung Kew ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Overall survival; Predictive factor; Transarterial chemolipiodolization with systemic chemo infusion; Treatment response

Indexed keywords

ALPHA FETOPROTEIN; CISPLATIN; EPIRUBICIN; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; IODINATED POPPYSEED OIL; AFP PROTEIN, HUMAN; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SIZE; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PROTEIN BLOOD LEVEL; RADIOLOGICAL PARAMETERS; RETROSPECTIVE STUDY; TRANSARTERIAL CHEMOLIPIODOLIZATION; TREATMENT RESPONSE; TUMOR VOLUME; AGED; BLOOD; CHEMOEMBOLIZATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISEASE COURSE; LIVER TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PREDICTIVE VALUE; RISK ASSESSMENT; RISK FACTOR; SCINTISCANNING; SOUTH KOREA; STATISTICAL MODEL; SURVIVAL; TIME; TREATMENT OUTCOME;

AGED; ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; DISEASE PROGRESSION; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LIVER NEOPLASMS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84863919105     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v18.i25.3215     Document Type: Article

References (37)

1. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745-750
2. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94: 153-156
3. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodés J. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421-430
4. Tandon P, Garcia-Tsao G. Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int 2009; 29: 502-510
5. Sugiyama M, Sakahara H, Torizuka T, Kanno T, Nakamura F, Futatsubashi M, Nakamura S. 18F-FDG PET in the detection of extrahepatic metastases from hepatocellular carcinoma. J Gastroenterol 2004; 39: 961-968
6. Trojan J, Schroeder O, Raedle J, Baum RP, Herrmann G, Jacobi V, Zeuzem S. Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma. Am J Gastroenterol 1999; 94: 3314-3319
7. Lee JD, Yun M, Lee JM, Choi Y, Choi YH, Kim JS, Kim SJ, Kim KS, Yang WI, Park YN, Han KH, Lee WJ, Yoo N, Lim SM, Park JH. Analysis of gene expression profiles of hepatocellular carcinomas with regard to 18F-fluorodeoxyglucose uptake pattern on positron emission tomography. Eur J Nucl Med Mol Imaging 2004; 31: 1621-1630
8. Yang SH, Suh KS, Lee HW, Cho EH, Cho JY, Cho YB, Yi NJ, Lee KU. The role of (18)F-FDG-PET imaging for the selection of liver transplantation candidates among hepatocellular carcinoma patients. Liver Transpl 2006; 12: 1655-1660
9. Cascales Campos P, Ramirez P, Gonzalez R, Febrero B, Pons JA, Miras M, Sanchez Bueno F, Robles R, Parrilla P. Value of 18-FDG-positron emission tomography/computed tomography before and after transarterial chemoembolization in pa tients with hepatocellular carcinoma undergoing liver trans plantation: initial results. Transplant Proc 2011; 43: 2213-2215
10. Kim HO, Kim JS, Shin YM, Ryu JS, Lee YS, Lee SG. Evaluation of metabolic characteristics and viability of lipiodolized hepatocellular carcinomas using 18F-FDG PET/CT. J Nucl Med 2010; 51: 1849-1856
11. Kirchhoff TD, Rudolph KL, Layer G, Chavan A, Greten TF, Rosenthal H, Kubicka S, Galanski M, Manns MP, Schild H, Gallkowski U. Chemoocclusion vs chemoperfusion for treatment of advanced hepatocellular carcinoma: a randomised trial. Eur J Surg Oncol 2006; 32: 201-207
12. Jang JW, Bae SH, Choi JY, Oh HJ, Kim MS, Lee SY, Kim CW, Chang UI, Nam SW, Cha SB, Lee YJ, Chun HJ, Choi BG, Byun JY, Yoon SK. A combination therapy with transarterial chemo-lipiodolization and systemic chemo-infusion for large extensive hepatocellular carcinoma invading portal vein in comparison with conservative management. Cancer Chemother Pharmacol 2007; 59: 9-15
13. Jang JW, Park YM, Bae SH, Choi JY, Yoon SK, Chang UI, Nam SW, Kim BS. Therapeutic efficacy of multimodal combination therapy using transcatheter arterial infusion of epirubicin and cisplatin, systemic infusion of 5-fluorouracil, and additional percutaneous ethanol injection for unresectable hepatocellular carcinoma. Cancer Chemother Pharmacol 2004; 54: 415-420
14. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30: 52-60
15. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247
16. Sweeney MJ, Ashmore J, Morris HP, Weber G. Comparative biochemistry hepatomas. IV. isotope studies of glucose and fructose metabolism in liver tumors of different growth rates. Cancer Res 1963; 23: 995-1002
17. Burk D, Woods M, Hunter J. On the significance of glucolysis for cancer growth, with special reference to Morris rat hepatomas. J Natl Cancer Inst 1967; 38: 839-863
18. Mocherla B, Kim J, Roayaie S, Kim S, Machac J, Kostakoglu L. FDG PET/CT imaging to rule out extrahepatic metastases before liver transplantation. Clin Nucl Med 2007; 32: 947-948
19. Okazumi S, Isono K, Enomoto K, Kikuchi T, Ozaki M, Yamamoto H, Hayashi H, Asano T, Ryu M. Evaluation of liver tumors using fluorine-18-fluorodeoxyglucose PET: characterization of tumor and assessment of effect of treatment. J Nucl Med 1992; 33: 333-339
20. Iwata Y, Shiomi S, Sasaki N, Jomura H, Nishiguchi S, Seki S, Kawabe J, Ochi H. Clinical usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose in the diagnosis of liver tumors. Ann Nucl Med 2000; 14: 121-126
21. Messa C, Choi Y, Hoh CK, Jacobs EL, Glaspy JA, Rege S, Nitzsche E, Huang SC, Phelps ME, Hawkins RA. Quantification of glucose utilization in liver metastases: parametric imaging of FDG uptake with PET. J Comput Assist Tomogr 1992; 16: 684-689
22. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J, Gores GJ. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 698-711
23. Lencioni R, Crocetti L. Local-regional treatment of hepatocellular carcinoma. Radiology 2012; 262: 43-58
24. Shen H, Agarwal D, Qi R, Chalasani N, Liangpunsakul S, Lumeng L, Yoo H, Kwo P. Predictors of outcome in patients with unresectable hepatocellular carcinoma receiving transcatheter arterial chemoembolization. Aliment Pharmacol Ther 2007; 26: 393-400
25. Bruix J, Llovet JM, Castells A, Montañá X, Brú C, Ayuso MC, Vilana R, Rodés J. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 1998; 27: 1578-1583
26. Raoul JL, Sangro B, Forner A, Mazzaferro V, Piscaglia F, Bolondi L, Lencioni R. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev 2011; 37: 212-220
27. Forner A, Llovet JM, Bruix J. Chemoembolization for intermediate HCC: is there proof of survival benefit? J Hepatol 2012; 56: 984-986
28. Seo S, Hatano E, Higashi T, Hara T, Tada M, Tamaki N, Iwaisako K, Ikai I, Uemoto S. Fluorine-18 fluorodeoxyglucose positron emission tomography predicts tumor differentiation, P-glycoprotein expression, and outcome after resection in hepatocellular carcinoma. Clin Cancer Res 2007; 13: 427-433
29. Sun L, Guan YS, Pan WM, Chen GB, Luo ZM, Wu H. Positron emission tomography/computer tomography in guidance of extrahepatic hepatocellular carcinoma metastasis management. World J Gastroenterol 2007; 13: 5413-5415
30. Kim BK, Kang WJ, Kim JK, Seong J, Park JY, Kim DY, Ahn SH, Lee DY, Lee KH, Lee JD, Han KH. (18) F-fluorodeoxyglucose uptake on positron emission tomography as a prognostic predictor in locally advanced hepatocellular carcinoma. Cancer 2011; Equb ahead of print
31. Yamamoto Y, Nishiyama Y, Kameyama R, Okano K, Kashiwagi H, Deguchi A, Kaji M, Ohkawa M. Detection of hepatocellular carcinoma using 11C-choline PET: comparison with 18F-FDG PET. J Nucl Med 2008; 49: 1245-1248
32. Sun L, Wu H, Pan WM, Guan YS. Positron emission tomography/computed tomography with (18)F-fluorodeoxyglucose identifies tumor growth or thrombosis in the portal vein with hepatocellular carcinoma. World J Gastroenterol 2007; 13: 4529-4532
33. Megyesi C, Samols E, Marks V. Glucose tolerance and diabetes in chronic liver disease. Lancet 1967; 2: 1051-1056
34. Petrides AS, DeFronzo RA. Glucose metabolism in cirrhosis: a review with some perspectives for the future. Diabetes Metab Rev 1989; 5: 691-709
35. Kornberg A, Küpper B, Thrum K, Katenkamp K, Steenbeck J, Sappler A, Habrecht O, Gottschild D. Increased 18F-FDG uptake of hepatocellular carcinoma on positron emission tomography independently predicts tumor recurrence in liver transplant patients. Transplant Proc 2009; 41: 2561-2563
36. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19: 329-338
37. Lin CY, Chen JH, Liang JA, Lin CC, Jeng LB, Kao CH. 18F-FDG PET or PET/CT for detecting extrahepatic metastases or recurrent hepatocellular carcinoma: A systematic review and meta-analysis. Eur J Radiol 2011; Equb ahead of print